ProMIS Cash And Short Term Investments from 2010 to 2024
| PMN Stock | USD 0.96 0.05 4.95% |
Cash And Short Term Investments | First Reported 2005-06-30 | Previous Quarter 1 M | Current Value 21.6 M | Quarterly Volatility 5.7 M |
Check ProMIS Neurosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProMIS Neurosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 46.1 K, Interest Expense of 191.3 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 5.1 K, Dividend Yield of 0.0 or PTB Ratio of 2.7. ProMIS financial statements analysis is a perfect complement when working with ProMIS Neurosciences Valuation or Volatility modules.
ProMIS | Cash And Short Term Investments |
Latest ProMIS Neurosciences' Cash And Short Term Investments Growth Pattern
Below is the plot of the Cash And Short Term Investments of ProMIS Neurosciences over the last few years. Short Term Investments is an account in the current assets section of ProMIS Neurosciences balance sheet. This account contains ProMIS Neurosciences investments that will expire within one year. These investments include stocks and bonds that can be liquidated by ProMIS Neurosciences fairly quickly. It is the sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash. ProMIS Neurosciences' Cash And Short Term Investments historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ProMIS Neurosciences' overall financial position and show how it may be relating to other accounts over time.
| Cash And Short Term Investments | 10 Years Trend |
|
Cash And Short Term Investments |
| Timeline |
ProMIS Cash And Short Term Investments Regression Statistics
| Arithmetic Mean | 5,209,993 | |
| Geometric Mean | 1,279,155 | |
| Coefficient Of Variation | 140.02 | |
| Mean Deviation | 5,732,944 | |
| Median | 1,703,539 | |
| Standard Deviation | 7,295,067 | |
| Sample Variance | 53.2T | |
| Range | 21.5M | |
| R-Value | 0.70 | |
| Mean Square Error | 29.1T | |
| R-Squared | 0.49 | |
| Significance | 0 | |
| Slope | 1,145,044 | |
| Total Sum of Squares | 745.1T |
ProMIS Cash And Short Term Investments History
About ProMIS Neurosciences Financial Statements
ProMIS Neurosciences investors utilize fundamental indicators, such as Cash And Short Term Investments, to predict how ProMIS Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cash And Short Term Investments | 16.8 M | 17.6 M |
Pair Trading with ProMIS Neurosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProMIS Neurosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProMIS Neurosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with ProMIS Stock
Moving against ProMIS Stock
| 0.78 | BMY | Bristol Myers Squibb | PairCorr |
| 0.72 | GILD | Gilead Sciences | PairCorr |
| 0.7 | ESPR | Esperion Therapeutics | PairCorr |
| 0.47 | FLGC | Flora Growth Corp | PairCorr |
| 0.47 | DNA | Ginkgo Bioworks Holdings | PairCorr |
The ability to find closely correlated positions to ProMIS Neurosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProMIS Neurosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProMIS Neurosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProMIS Neurosciences to buy it.
The correlation of ProMIS Neurosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProMIS Neurosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProMIS Neurosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProMIS Neurosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of ProMIS Neurosciences Correlation against competitors. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.04 | Revenue Per Share 0.001 | Return On Assets (4.81) | Return On Equity (10.99) |
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.